Salarius Pharmaceuticals, Inc. (SLRX)
Largest Insider Buys in Sector
SLRX Stock Price History Chart
SLRX Stock Performance
About Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect …
Insider Activity of Salarius Pharmaceuticals, Inc.
Over the last 12 months, insiders at Salarius Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Salarius Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Salarius Pharmaceuticals, Inc. have bought $71,551 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 37,500 shares for transaction amount of $7,016 was made by Lieber Jonathan I () on 2022‑06‑07.
List of Insider Buy and Sell Transactions, Salarius Pharmaceuticals, Inc.
| 2022-06-07 | 37,500 0.0703% | $0.19 | $7,016 | -53.27% | ||||
| 2022-06-07 | 27,700 0.0499% | $0.18 | $4,986 | -53.27% | ||||
| 2022-06-06 | 26,553 0.0492% | $0.19 | $5,000 | -53.68% | ||||
| 2022-06-03 | 28,000 0.0521% | $0.18 | $5,152 | -52.08% | ||||
| 2022-05-31 | Exec VP Finance, CFO | 28,000 0.0522% | $0.18 | $5,040 | -50.75% | |||
| 2022-05-26 | Chief Executive Officer | 10,800 0.0206% | $0.18 | $1,990 | -50.53% | |||
| 2022-03-03 | Chief Executive Officer | 139,488 0.3016% | $0.39 | $54,540 | -51.33% | |||
| 2022-03-03 | Exec VP Finance, CFO | 76,246 0.1648% | $0.39 | $29,812 | -51.33% | |||
| 2021-08-17 | Chief Executive Officer | 4,000 0.0091% | $0.90 | $3,582 | -49.84% | |||
| 2021-08-10 | director | 7,000 0.0156% | $0.88 | $6,167 | -48.23% | |||
| 2020-08-21 | director | 4,000 0.0226% | $0.98 | $3,920 | +10.72% | |||
| 2020-08-19 | Chief Executive Officer | 2,000 0.011% | $1.01 | $2,020 | +4.41% | |||
| 2020-08-17 | Exec VP Finance, CFO | 5,000 0.0282% | $1.00 | $5,000 | +7.79% | |||
| 2020-02-19 | Exec VP Finance, CFO | 2,000 0.0208% | $0.95 | $1,900 | -5.19% | |||
| 2020-02-18 | Chief Business Officer | 11,300 0.1185% | $0.90 | $10,170 | +1.11% | |||
| 2020-02-13 | Exec VP Finance, CFO | 5,000 0.0506% | $0.86 | $4,295 | +0.72% | |||
| 2020-02-11 | director | 8,700 0.1255% | $1.15 | $10,005 | +6.95% | |||
| 2020-02-11 | Chief Executive Officer | 2,175 0.0314% | $1.15 | $2,501 | +6.95% | |||
| 2020-02-11 | director | 8,700 0.1255% | $1.15 | $10,005 | +6.95% | |||
| 2020-02-11 | director | 8,700 0.1255% | $1.15 | $10,005 | +6.95% |
Insider Historical Profitability
| MacKinnon Roderick | director | 431277 29.9257% | $1.51 | 1 | 0 | |
| Northrup Jonathan P | director | 352713 24.4742% | $1.51 | 1 | 0 | +6.95% |
| Arthur David J. | Chief Executive Officer | 303574 21.0646% | $1.51 | 5 | 0 | <0.0001% |
| Rosenblum Mark J | Exec VP Finance, CFO | 148319 10.2916% | $1.51 | 5 | 0 | <0.0001% |
| Wessel Thomas | Chief Medical Officer | 57064 3.9596% | $1.51 | 2 | 0 |
Institutional Investor Ownership
| Armistice Capital Llc | $44.4M | 14.07 | 84,000 | -4.54% | -$2.11M | 0.14 | |
| Horizon Kinetics LLC | $16.44M | 5.21 | 31,094 | 0% | +$0 | 0.19 | |
| Renaissance Technologies | $15,000.00 | 4.73 | 28,242 | +6.81% | +$956.02 | <0.0001 | |
| Geode Capital Management | $13.09M | 4.15 | 24,771 | 0% | +$0 | <0.01 | |
| The Vanguard Group | $7.7M | 2.44 | 14,563 | 0% | +$0 | <0.0001 |